Related Experiment Videos
Absorption of alpha-MSH from subcutaneous and intraperitoneal sites in the rat
Abstract:
Pentobarbitone anesthetized rats were injected with 30 nmol (50 micrograms) alpha-MSH administered intraperitoneally (IP) and subcutaneously (SC) in an acid-saline vehicle, or SC in a zinc phosphate vehicle. Concentrations of alpha-MSH in plasma were measured by radioimmunoassay. The pharmacokinetic parameters for the three modes of administration were determined by fitting a one-compartment open model to the plasma level data. The t1/2 for absorption using the saline vehicle was 7.3 and 5.6 min from the IP and SC sites, respectively. The t1/2 for absorption from the zinc phosphate complex of 17.7 min was significantly longer. Five percent of the IP dose was absorbed into the systemic circulation giving a peak plasma level of 14.1 nmol/l. The absorption of 2-3 percent was significantly lower following SC administration; peak plasma levels were 8.3 and 4.8 nmol/l for the saline and zinc phosphate vehicles, respectively. The low percentage absorption values indicated a high degree of metabolism of the peptide by peripheral tissues on its passage from the injection sites into the circulation.
Insights
Alpha-melanocyte-stimulating hormone (alpha-MSH) absorption varied by administration route. Zinc phosphate vehicle prolonged absorption time compared to saline, with low overall systemic bioavailability indicating significant peripheral metabolism.
Area of Science:
- Pharmacokinetics
- Endocrinology
- Drug Delivery
Background:
- Alpha-melanocyte-stimulating hormone (alpha-MSH) is a peptide hormone with various physiological roles.
- Understanding the pharmacokinetic profile of alpha-MSH is crucial for its therapeutic applications.
- Peptide drug delivery often faces challenges like poor absorption and rapid metabolism.
Purpose of the Study:
- To investigate the pharmacokinetics of alpha-MSH following intraperitoneal (IP) and subcutaneous (SC) administration in rats.
- To compare the absorption characteristics of alpha-MSH when administered in acid-saline versus zinc phosphate vehicles.
- To determine the systemic bioavailability and absorption rates of alpha-MSH via different routes and formulations.
Main Methods:
- Alpha-MSH (30 nmol) was administered IP and SC to pentobarbitone-anesthetized rats using acid-saline or zinc phosphate vehicles.
- Plasma alpha-MSH concentrations were quantified using radioimmunoassay.
- Pharmacokinetic parameters were determined by fitting a one-compartment open model to the plasma concentration-time data.
Main Results:
- The half-life of absorption (t1/2) for the saline vehicle was 7.3 min (IP) and 5.6 min (SC).
- The zinc phosphate vehicle resulted in a significantly longer absorption half-life of 17.7 min.
- Systemic absorption was low: 5% for IP and 2-3% for SC administration, with peak plasma levels of 14.1 nmol/L (IP), 8.3 nmol/L (SC saline), and 4.8 nmol/L (SC zinc phosphate).
Conclusions:
- Intraperitoneal and subcutaneous administration of alpha-MSH exhibit distinct pharmacokinetic profiles.
- The zinc phosphate vehicle significantly delays the absorption of alpha-MSH compared to a saline vehicle.
- Low systemic bioavailability suggests substantial peripheral metabolism of alpha-MSH during its passage into circulation.